PE20140040A1 - Composicion farmaceutica que comprende un inhibidor de la actividad de mek - Google Patents
Composicion farmaceutica que comprende un inhibidor de la actividad de mekInfo
- Publication number
- PE20140040A1 PE20140040A1 PE2013001442A PE2013001442A PE20140040A1 PE 20140040 A1 PE20140040 A1 PE 20140040A1 PE 2013001442 A PE2013001442 A PE 2013001442A PE 2013001442 A PE2013001442 A PE 2013001442A PE 20140040 A1 PE20140040 A1 PE 20140040A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitor
- pharmaceutical composition
- mek activity
- composition including
- amount
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 abstract 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 239000005913 Maltodextrin Substances 0.000 abstract 1
- 229920002774 Maltodextrin Polymers 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- 229920000881 Modified starch Polymers 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003086 colorant Substances 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 229940035034 maltodextrin Drugs 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA EN FORMA DE COMPRIMIDO QUE COMPRENDE: A) UN INHIBIDOR DE LA ACTIVIDAD DE MEK TAL COMO EL SOLVATO DE DIMETILSULFOXIDO DE N-{3-[3-CICLOPROPIL-5-(2-FLUORO-4-YODO-FENILAMINO)-6,8-DIMETIL-2,4,7-TRIOXO-3,4,6,7-TETRAHIDRO-2H-PIRIDO[4,3-d]PIRIMIDIN-1-IL]FENIL}ACETAMIDA EN UNA CANTIDAD DE 0,5635MG A 2,254MG; Y B) UNO O MAS EXCIPIENTES TALES COMO CELULOSA MICROCRISTALINA, ALMIDON PREGELATINIZADO, LACTOSA, MANITOL, MALTODEXTRINA, ENTRE OTROS, EN UNA CANTIDAD DE 25% A 89% EN PESO; EN DONDE EL COMPRIMIDO SE REVISTE CON UNA PELICULA LA CUAL CONTIENE UN COLORANTE TAL COMO OXIDO DE HIERRO. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE CANCER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061424967P | 2010-12-20 | 2010-12-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20140040A1 true PE20140040A1 (es) | 2014-02-26 |
Family
ID=46314827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013001442A PE20140040A1 (es) | 2010-12-20 | 2011-12-20 | Composicion farmaceutica que comprende un inhibidor de la actividad de mek |
Country Status (38)
| Country | Link |
|---|---|
| US (5) | US8580304B2 (es) |
| EP (4) | EP4159205B1 (es) |
| JP (2) | JP6126014B2 (es) |
| KR (1) | KR101911109B1 (es) |
| CN (1) | CN103998041B (es) |
| AR (2) | AR084102A1 (es) |
| AU (1) | AU2011349422B2 (es) |
| BR (1) | BR112013015602B1 (es) |
| CA (1) | CA2822701C (es) |
| CL (1) | CL2013001779A1 (es) |
| CR (1) | CR20130352A (es) |
| CY (1) | CY1123376T1 (es) |
| DK (3) | DK2654736T3 (es) |
| DO (1) | DOP2013000138A (es) |
| EA (1) | EA025198B1 (es) |
| ES (3) | ES2985024T3 (es) |
| FI (2) | FI4159205T3 (es) |
| HR (3) | HRP20240563T1 (es) |
| HU (3) | HUE066525T2 (es) |
| IL (1) | IL226855A (es) |
| JO (1) | JO3594B1 (es) |
| LT (3) | LT2654736T (es) |
| MA (1) | MA34883B1 (es) |
| MX (1) | MX2013007073A (es) |
| MY (1) | MY170501A (es) |
| NZ (1) | NZ612157A (es) |
| PE (1) | PE20140040A1 (es) |
| PH (1) | PH12013501209A1 (es) |
| PL (3) | PL2654736T3 (es) |
| PT (3) | PT4159204T (es) |
| RS (2) | RS65497B1 (es) |
| SG (1) | SG191054A1 (es) |
| SI (3) | SI4159205T1 (es) |
| TW (1) | TWI505828B (es) |
| UA (1) | UA113158C2 (es) |
| UY (1) | UY33818A (es) |
| WO (1) | WO2012088033A2 (es) |
| ZA (1) | ZA201304189B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產（第二）有限公司 | 新穎醫藥組成物 |
| KR20150038068A (ko) | 2012-08-17 | 2015-04-08 | 에프. 호프만-라 로슈 아게 | 코비메티닙 및 베무라피닙을 투여함을 포함하는 흑색종의 조합 치료법 |
| US20150328320A1 (en) * | 2012-11-30 | 2015-11-19 | Glaxosmithkline Llc | Novel Pharmaceutical Composition |
| WO2015019125A1 (en) * | 2013-08-05 | 2015-02-12 | Societe De Developpement Et De Recherche Industrielle | Molecular targets for the treatment of wounds, in particular chronic wounds |
| CN103819471A (zh) * | 2013-11-25 | 2014-05-28 | 镇江圣安医药有限公司 | 吡啶并(4,3-d)嘧啶-1（2H）-基苯基乙酰胺的衍生物及其应用 |
| WO2015081566A1 (zh) * | 2013-12-06 | 2015-06-11 | 杭州普晒医药科技有限公司 | 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途 |
| EP2913048A1 (en) * | 2014-02-27 | 2015-09-02 | ratiopharm GmbH | Pharmaceutical composition comprising trametinib |
| KR101545268B1 (ko) | 2015-02-05 | 2015-08-20 | 보령제약 주식회사 | 정제 및 이의 제조방법 |
| WO2016126012A1 (en) * | 2015-02-05 | 2016-08-11 | Boryung Pharmaceutical Co., Ltd | Tablet and method of preparing the same |
| US20170020880A1 (en) * | 2015-07-22 | 2017-01-26 | Hetero Research Foundation | Pharmaceutical compositions of trametinib |
| CN116172869A (zh) * | 2016-08-10 | 2023-05-30 | 豪夫迈·罗氏有限公司 | 包含Akt蛋白激酶抑制剂的药物组合物 |
| RU2627692C1 (ru) * | 2016-10-10 | 2017-08-10 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2 |
| WO2018095403A1 (zh) | 2016-11-25 | 2018-05-31 | 江苏恒瑞医药股份有限公司 | 一种吡啶酮类衍生物药物组合物及其制备方法 |
| IL311471A (en) | 2017-05-02 | 2024-05-01 | Novartis Ag | Combination therapy |
| EP4563150A3 (en) | 2019-05-13 | 2025-07-23 | Novartis AG | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer |
| EP3996746A4 (en) | 2019-07-11 | 2023-08-23 | Praxis Precision Medicines, Inc. | T-TYPE CALCIUM CHANNEL MODULATOR FORMULATIONS AND METHODS OF USE THEREOF |
| EP4007585A4 (en) | 2019-08-02 | 2023-11-08 | OneHealthCompany, Inc. | TREATMENT OF CANINE CANCERS |
| RU2749719C1 (ru) * | 2020-10-08 | 2021-06-16 | Нестерук Владимир Викторович | Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения |
| EP4444299A1 (en) | 2021-12-06 | 2024-10-16 | My Personal Therapeutics Ltd | A combination treatment for cancer |
| WO2024171019A1 (en) * | 2023-02-13 | 2024-08-22 | Alembic Pharmaceuticals Limited | Pharmaceutical composition of trametinib and process of preparation thereof |
| WO2025132408A2 (en) | 2023-12-21 | 2025-06-26 | Synthon B.V. | Solvates of trametinib |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4727077A (en) | 1985-02-20 | 1988-02-23 | Ishihara Sangyo Kaisha Ltd. | Benzoyl urea compounds, process for their production, and antitumorous compositions containing them |
| JPS61205257A (ja) * | 1985-03-08 | 1986-09-11 | Ishihara Sangyo Kaisha Ltd | ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤 |
| US5559235A (en) | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
| US5342947A (en) | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| US5491237A (en) | 1994-05-03 | 1996-02-13 | Glaxo Wellcome Inc. | Intermediates in pharmaceutical camptothecin preparation |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6825180B2 (en) | 2001-05-18 | 2004-11-30 | Cell Therapeutics, Inc. | Pyridopyrimidine compounds and their uses |
| PL2298768T3 (pl) * | 2004-06-11 | 2013-03-29 | Japan Tobacco Inc | Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-d]pirymidyny i związki pokrewne do leczenia nowotworu |
| US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| US7955622B2 (en) * | 2006-10-13 | 2011-06-07 | Actavis Group Ptc Hf | Controlled-release galantamine formulations |
| US20080145433A1 (en) * | 2006-11-09 | 2008-06-19 | Gilead Colorado, Inc. | Darusentan oral dosage form |
| JO2985B1 (ar) * | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| ECSP077628A (es) * | 2007-05-03 | 2008-12-30 | Smithkline Beechman Corp | Nueva composición farmacéutica |
| EP2175885B1 (en) * | 2007-07-30 | 2016-10-12 | Ardea Biosciences, Inc. | Combinations of mek inhibitors and raf kinase inhibitors and uses thereof |
| CA2700844A1 (en) * | 2007-09-25 | 2009-04-02 | Teva Pharmaceutical Industries Ltd. | Stable imatinib compositions |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| AU2009267683B2 (en) * | 2008-07-08 | 2014-04-03 | Beta Pharma, Inc. | Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof |
| JP2013505939A (ja) | 2009-09-23 | 2013-02-21 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 組合せ |
| AU2010298280B2 (en) | 2009-09-23 | 2014-07-03 | Novartis Ag | Combination |
| JP2013505962A (ja) | 2009-09-28 | 2013-02-21 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 組合せ |
| PT2488033T (pt) | 2009-10-16 | 2019-09-10 | Novartis Ag | Combinação que compreende um inibidor de mek e um inibidor de b-raf |
| ES2578191T3 (es) | 2009-11-17 | 2016-07-21 | Novartis Ag | Combinación |
| JP5903433B2 (ja) | 2010-08-26 | 2016-04-13 | ノバルティス アーゲー | 癌の治療に有用なｖｅｇｆｒ阻害剤およびｍｅｋ阻害剤の医薬的組み合わせ |
| TWI505828B (zh) | 2010-12-20 | 2015-11-01 | 葛蘭素史克智慧財產（第二）有限公司 | 新穎醫藥組成物 |
| US8977217B1 (en) | 2013-02-20 | 2015-03-10 | Triquint Semiconductor, Inc. | Switching device with negative bias circuit |
| CZ2015278A3 (cs) | 2015-04-24 | 2016-11-02 | Zentiva, K.S. | Krystalické formy trametinibu |
-
2011
- 2011-12-16 TW TW100146692A patent/TWI505828B/zh active
- 2011-12-18 JO JOP/2011/0385A patent/JO3594B1/ar active
- 2011-12-19 UY UY0001033818A patent/UY33818A/es active IP Right Grant
- 2011-12-19 AR ARP110104773A patent/AR084102A1/es not_active Application Discontinuation
- 2011-12-20 HR HRP20240563TT patent/HRP20240563T1/hr unknown
- 2011-12-20 EP EP22209107.6A patent/EP4159205B1/en active Active
- 2011-12-20 SI SI201132108T patent/SI4159205T1/sl unknown
- 2011-12-20 PH PH1/2013/501209A patent/PH12013501209A1/en unknown
- 2011-12-20 AU AU2011349422A patent/AU2011349422B2/en active Active
- 2011-12-20 FI FIEP22209107.6T patent/FI4159205T3/fi active
- 2011-12-20 EP EP20179788.3A patent/EP3808343A1/en active Pending
- 2011-12-20 SI SI201132109T patent/SI4159204T1/sl unknown
- 2011-12-20 JP JP2013546310A patent/JP6126014B2/ja active Active
- 2011-12-20 DK DK11849974.8T patent/DK2654736T3/da active
- 2011-12-20 ES ES22209107T patent/ES2985024T3/es active Active
- 2011-12-20 EA EA201390913A patent/EA025198B1/ru not_active IP Right Cessation
- 2011-12-20 MY MYPI2013701038A patent/MY170501A/en unknown
- 2011-12-20 PE PE2013001442A patent/PE20140040A1/es active IP Right Grant
- 2011-12-20 HR HRP20201409TT patent/HRP20201409T1/hr unknown
- 2011-12-20 MX MX2013007073A patent/MX2013007073A/es active IP Right Grant
- 2011-12-20 EP EP22209104.3A patent/EP4159204B1/en active Active
- 2011-12-20 FI FIEP22209104.3T patent/FI4159204T3/fi active
- 2011-12-20 PT PT222091043T patent/PT4159204T/pt unknown
- 2011-12-20 HU HUE22209104A patent/HUE066525T2/hu unknown
- 2011-12-20 UA UAA201309128A patent/UA113158C2/uk unknown
- 2011-12-20 PT PT222091076T patent/PT4159205T/pt unknown
- 2011-12-20 CN CN201180066851.0A patent/CN103998041B/zh active Active
- 2011-12-20 PL PL11849974T patent/PL2654736T3/pl unknown
- 2011-12-20 DK DK22209107.6T patent/DK4159205T3/da active
- 2011-12-20 SI SI201131918T patent/SI2654736T1/sl unknown
- 2011-12-20 HR HRP20240564TT patent/HRP20240564T1/hr unknown
- 2011-12-20 ES ES11849974T patent/ES2820536T3/es active Active
- 2011-12-20 NZ NZ612157A patent/NZ612157A/en unknown
- 2011-12-20 LT LTEP11849974.8T patent/LT2654736T/lt unknown
- 2011-12-20 US US13/330,949 patent/US8580304B2/en active Active
- 2011-12-20 WO PCT/US2011/066021 patent/WO2012088033A2/en not_active Ceased
- 2011-12-20 HU HUE11849974A patent/HUE050788T2/hu unknown
- 2011-12-20 DK DK22209104.3T patent/DK4159204T3/da active
- 2011-12-20 PL PL22209104.3T patent/PL4159204T3/pl unknown
- 2011-12-20 EP EP11849974.8A patent/EP2654736B1/en not_active Revoked
- 2011-12-20 KR KR1020137019029A patent/KR101911109B1/ko active Active
- 2011-12-20 MA MA36106A patent/MA34883B1/fr unknown
- 2011-12-20 RS RS20240519A patent/RS65497B1/sr unknown
- 2011-12-20 BR BR112013015602-3A patent/BR112013015602B1/pt active IP Right Grant
- 2011-12-20 CA CA2822701A patent/CA2822701C/en active Active
- 2011-12-20 PL PL22209107.6T patent/PL4159205T3/pl unknown
- 2011-12-20 ES ES22209104T patent/ES2982775T3/es active Active
- 2011-12-20 LT LTEP22209107.6T patent/LT4159205T/lt unknown
- 2011-12-20 US US13/991,705 patent/US20130266649A1/en not_active Abandoned
- 2011-12-20 HU HUE22209107A patent/HUE066526T2/hu unknown
- 2011-12-20 RS RS20240518A patent/RS65496B1/sr unknown
- 2011-12-20 SG SG2013044037A patent/SG191054A1/en unknown
- 2011-12-20 LT LTEP22209104.3T patent/LT4159204T/lt unknown
- 2011-12-20 PT PT118499748T patent/PT2654736T/pt unknown
-
2013
- 2013-06-07 ZA ZA2013/04189A patent/ZA201304189B/en unknown
- 2013-06-10 IL IL226855A patent/IL226855A/en active IP Right Grant
- 2013-06-18 DO DO2013000138A patent/DOP2013000138A/es unknown
- 2013-06-18 CL CL2013001779A patent/CL2013001779A1/es unknown
- 2013-07-19 CR CR20130352A patent/CR20130352A/es unknown
- 2013-10-02 US US14/044,139 patent/US9271941B2/en active Active
- 2013-12-11 US US14/103,092 patent/US9399021B2/en active Active
- 2013-12-11 US US14/103,193 patent/US9155706B2/en active Active
-
2017
- 2017-01-19 JP JP2017007796A patent/JP2017137299A/ja not_active Withdrawn
-
2020
- 2020-09-24 CY CY20201100905T patent/CY1123376T1/el unknown
-
2021
- 2021-05-27 AR ARP210101433A patent/AR122185A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20140040A1 (es) | Composicion farmaceutica que comprende un inhibidor de la actividad de mek | |
| IL238476B (en) | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes | |
| PH12016500793A1 (en) | Turmeric extract containing soft pastilles | |
| PE20151786A1 (es) | Compuestos heterociclicos y sus usos | |
| MX2014015005A (es) | Formas cristalinas de un modulador del receptor androgenico. | |
| UY35916A (es) | Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio | |
| CU20140141A7 (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas | |
| GT201400043A (es) | Imidazopiridazinas sustituidas con amino | |
| MX342409B (es) | Tratamiento de enfermedades cardiacas. | |
| UY31228A1 (es) | Ariloxazoles sustituidos y su uso | |
| AR083162A1 (es) | Uso de ingredientes activos para controlar nematodos en cultivos resistentes a nematodos | |
| GT201500053A (es) | Composicion farmaceutica recubierta que contiene regorafenib | |
| UY35040A (es) | Pirrolopirimidinilamino-benzotiazolonas sustituidas | |
| GT201200293A (es) | Marcadores predictivos útiles en el tratamiento del síndrome frágil x (fxs) | |
| CO6640327A2 (es) | Compuestos de pirazol como inhibidores del receptor sigma | |
| BR112013003965A2 (pt) | uso de açúcares em uma matriz de estabilização e composições sólidas | |
| TWD168062S (zh) | 鞋墊 | |
| ECSP18071568A (es) | Agente microbiano de suministro directo para la prevención de una patología del camarón | |
| NI201100155A (es) | Composiciones y métodos para el tratamiento prolongado con aminopiridinas | |
| CL2016001570A1 (es) | Uso de un antagonista de receptores de opioides con actividad %u039a y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas | |
| ECSP15022442A (es) | Producto de comicronización que comprende acetato de ulipristal | |
| AR083095A1 (es) | Cocristal de aprepitant l-prolina y composicion farmaceutica | |
| GT201300032A (es) | Composicion farmaceutica de liberacion prolongada de trimetazidina | |
| CL2013001445A1 (es) | Compuestos derivados de difenilamina; composicion farmaceutica y uso en el tratamiento de enfermedades inflamatorias, tales como cancer. | |
| TWD154764S (zh) | 凳椅 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |